Crystal form of sodium-glucose cotransporter 2 inhibitor
The present invention relates to a crystalline form of a co-crystal of an inhibitor against sodium-glucose cotransporter 2 with L-proline, a method for preparing the same, a pharmaceutical composition comprising the same, and use thereof. Specifically, the present invention relates to a crystalline form of a co-crystal of an inhibitor against sodium-glucose cotransporter 2 represented by formula (1), i.e., (2S,3R,4R,5S,6R)-2-(3-(4-(((1R,3s,5S)-bicyclo[3.1.0]hexan-3-yl)oxy)benzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, with L-proline, a method for preparing the same, a pharmaceutical composition comprising the same, and use thereof.
1. Crystalline Form I of a co-crystal of the compound of Formula (1) with L-proline, wherein the compound of Formula (1) is (2S,3R,4R,5S,6R)-2-(3-(4-(((1R,3s,5S)-bicyclo[3.1.0]hexan-3-yl)oxy)benzyl)-4-chlorophenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, the compound of Formula (1) with L-proline are present in a molar ratio of 1:2,
the crystalline Form I exhibits an X-ray powder diffraction pattern having characteristic peaks at the 2θ positions of 4.0±0.2°, 17.9±0.2°, 18.5±0.2° and 19.7±0.2°, as determined by using Cu-Kα radiation,
2. The crystalline Form I according to claim 1 , wherein the X-ray powder diffraction pattern further has characteristic peaks at the 2θ positions of 12.5±0.2°, 13.7±0.2° and 15.0±0.2°, as determined by using Cu-Kα radiation.
3. The crystalline Form I according to claim 2 , wherein the X-ray powder diffraction pattern further has characteristic peaks at the 2θ positions of 11.3±0.2°, 16.5±0.2° and 24.2±0.2°, as determined by using Cu-Kα radiation.
4. The crystalline Form I according to claim 3 , wherein the X-ray powder diffraction pattern further has characteristic peaks at the 2θ positions of 15.5±0.2°, 19.0±0.2° and 22.7±0.2°, as determined by using Cu-Kα radiation.
5. The crystalline Form I according to claim 1 , which exhibits a differential scanning calorimetry thermogram having an endothermic conversion peak at the range from 130° C. to 170° C.
6. The crystalline Form I according to claim 5 , wherein the differential scanning calorimetry thermogram has the endothermic conversion peak at the range from 140° C. to 160° C.
7. A method for preparing the crystalline Form I according to claim 1 , including the steps of: dissolving the compound of the Formula (1) and L-proline in a single solvent or a mixed solvent under a heating condition to produce a solution; then heating the solution to a certain temperature; maintaining the temperature for a certain period of time; cooling the solution to form a crystal; and isolating and drying the crystal to obtain the crystalline Form I.
8. A method for preparing the crystalline Form I according to claim 1 , including the steps of: dissolving the compound of the Formula (1) and L-proline in a single solvent or a mixed solvent under a heating condition; adding an organic solvent thereto to produce a solution; cooling the solution to form a crystal; and then isolating and drying the crystal to obtain the crystalline Form I.
9. The method according to claim 7 , wherein the single solvent is selected from the group consisting of: alcohols, esters, ketones, nitriles, and oxygen-containing heterocycles, and the mixed solvent is selected from the group consisting of: a mixture of alcohol and water, a mixture of ketone and water, a mixture of nitrile and water, and a mixture of oxygen-containing heterocycle and water.
10. The method according to claim 8 , wherein the organic solvent is selected from the group consisting of alcohols, ketones, esters, ethers, nitriles, alkanes, and any mixtures thereof.
11. The method according to claim 9 , wherein the single solvent is selected from the group consisting of lower alcohols and ketones.
12. A pharmaceutical composition comprising the crystalline Form I according to claim 1 and one or more pharmaceutically acceptable carrier, wherein the pharmaceutical composition is suitable for being formulated into any of pharmaceutically acceptable dosage forms.
13. The method according to claim 8 , wherein the single solvent is selected from the group consisting of: alcohols, esters, ketones, nitriles, and oxygen-containing heterocycles, and the mixed solvent is selected from the group consisting of: a mixture of alcohol and water, a mixture of ketone and water, a mixture of nitrile and water, and a mixture of oxygen-containing heterocycle and water.
14. The method according to claim 9 , wherein the single solvent is selected from the group consisting of methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, tert-butanol, acetone, and butanone.
15. The method according to claim 10 , wherein the single solvent is selected from the group consisting of lower alcohols and ketones; and the organic solvent is selected from the group consisting of saturated hydrocarbons and alcohol/saturated hydrocarbon.
16. The method according to claim 15 , wherein the single solvent is selected from the group consisting of methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, tert-butanol, acetone, and butanone.
17. The method according to claim 15 , wherein the organic solvent is selected from the group consisting of n-pentane, isopentane, n-hexane, isohexane, cyclohexane, and ethanol/n-hexane.
18. A method for treating non-insulin dependent diabetes mellitus or a complication thereof, an insulin resistance disease or obesity, comprising administering to a patient the crystalline Form I according to claim 1 .